Common use of Transfer of Human Material Clause in Contracts

Transfer of Human Material. (a) The Parties will ensure that each Research Project is approved by NCI, the Recipient CIMAC(s), and the CIDC before the transfer of any Human Material from the Provider to the Recipient CIMAC(s). NCI approval includes the requirement of review of any agreements between or among Provider and NCI/Pharma Collaborator(s) related to the Human Material, to ensure the terms comply with the CIMAC-CIDC Guidelines and with this Agreement. (b) Biospecimens that are transferred from the Provider to a Recipient CIMAC will not be redistributed from such Recipient CIMAC to another CIMAC (regardless of whether such CIMAC is a Recipient CIMAC or otherwise) unless approved in writing by NCI. The Provider shall retain title to Biospecimens. (c) Transfer of the Human Material outside of the CIMAC-CIDC will require the prior written permission of the Provider and, for NCI-supported Protocols, NCI, as well as an appropriate transfer agreement between the CIMAC-CIDC and the non-CIMAC-CIDC recipient that contains restrictions and obligations that are consistent with this Agreement. (d) Provider is responsible for transferring the CLIA form concurrently with the Biospecimens if a CLIA assay is going to be performed on the Biospecimens. (e) Provider will transfer the Specimen Tracking Manifest to Recipient CIMACs and CIDC as directed by NCI concurrently with the transfer of the Biospecimens.

Transfer of Human Material. (a) The Parties will ensure that each Research Project is approved by NCI, the Recipient CIMAC(s), and the CIDC NCI before the transfer of any Human Material from the Provider to the Recipient CIMAC(s)Provider. NCI approval includes the requirement of review of any agreements between or among Provider and NCI/Pharma Collaborator(s) Collaborator related to the Human Material, to ensure the terms comply with the CIMAC-CIDC Guidelines Guidelines. If approved under the Research Project and with covered by this Agreement. (bAgreement or another CIMAC-CIDC HMTA, the Human Material may be transferred by the Provider to the CIMACs specified in the relevant agreement(s) under a LoT. Provider will ensure that NCI receives a copy of each LoT. Biospecimens that are transferred from the Provider to a Recipient CIMAC will not be redistributed from such that Recipient CIMAC to another non-recipient CIMAC (regardless of whether such CIMAC is a Recipient CIMAC or otherwise) unless approved in writing by NCI. The Provider shall retain title to Biospecimens. (c) Transfer of the Human Material outside of the CIMAC-CIDC will require the prior written permission of the Provider and, for NCI-supported Protocols, NCI, as well as an appropriate transfer agreement between the CIMAC-CIDC and the non-CIMAC-CIDC recipient that contains restrictions and obligations that are consistent with this Agreement. (d) . Provider is responsible for transferring the CLIA form concurrently with the Biospecimens if a CLIA assay is going to be performed on the Biospecimens. (e) . Provider will transfer the Specimen Tracking Manifest to Recipient CIMACs and CIDC Recipients as directed by NCI concurrently with the transfer of the Biospecimens.